Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 7/20 | 0.35 |
| ▸ | FAP | Q12884 | 5/20 | 0.35 |
| ▸ | PREP | P48147 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181297 | 0.88 | FAP (0.38) | L3MBTL1POLBKDM4EALDH1A1EPHX2 | |
| SCHEMBL25221067 | 0.86 | SMN1; SMN2 (0.40) | L3MBTL1POLBKDM4EALDH1A1KMT2A | |
| SCHEMBL25293272 | 0.86 | SMN1; SMN2 (0.40) | L3MBTL1POLBKDM4EALDH1A1KMT2A | |
| SCHEMBL5643023 | 0.84 | POLB (0.42) | L3MBTL1POLBFFAR1DPP4HRH3 | |
| SCHEMBL28153696 | 0.84 | POLB (0.42) | L3MBTL1POLBFFAR1DPP4HRH3 | |
| SCHEMBL337262 | 0.82 | SMN1; SMN2 (0.45) | L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL9354741 | 0.82 | SMN1; SMN2 (0.45) | L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL19947264 | 0.81 | POLB (0.40) | L3MBTL1POLBKMT2AFFAR1EPHX2 | |
| SCHEMBL19947263 | 0.81 | POLB (0.40) | L3MBTL1POLBKMT2AFFAR1EPHX2 | |
| SCHEMBL1779547 | 0.80 | L3MBTL1 (0.38) | L3MBTL1POLBKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | L3MBTL1 4767/4885POLB 3253/4885KDM4E 1960/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | L3MBTL1 2427/4885POLB 3030/4885KDM4E 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.